India's Sun brings home Taro CEO as business plan accelerates

Indian flag

Mumbai-based Sun Pharmaceutical Industries has decided to bring the CEO of its Taro unit--Kal Sundaram--back from the U.S. to the head office in India by the end of the year as plans to consolidate manufacturing and other operations ramp up. 

Sundaram headed Taro following an acrimonious takeover effort by Sun's MD and founder, Dilip Shanghvi, from the Israel-based founders that ended in 2010.

He helped steer the previously unprofitable company to sales of $950 million in the year ending March of this year, with net profit hitting $450 million, according to the Economic Times.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

In earnings for the year ended March 31, released in May, Sun--the world's fifth largest generics maker--said it was confident a massive reorganization to consolidate operations after its purchase of Ranbaxy Laboratories in 2014 were "on track," and in particular lauded progress in the U.S. market.

A replacement for Sundaram at Taro and the exact title of his new role at headquarters were not announced.

- here's the release
- and a story from the Economic Times

Related Articles:
India's Sun says consolidation efforts on track, eyes share buyback

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.